I don't expect revenues. I don't expect a partnership announcement unless there's an accompanying PR. We may or may not get the upcoming LymPro revenue projections, but I expect those may also be a separate PR and also discussed in the conference call after the 10-Q filing.
We'll get the most recent update for number of shares issued, and a better idea of the cash burn rate since the last quarter.
Other than that, I expect just the typical 10-Q info.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links